ENSC Stock — Ensysce Biosciences Inc

Ensysce Biosciences Inc (ENSC)

Updated October 16, 2026.

ENSC is a Stock. Total return is -100.0% over the past 8.6 years, 313.6 points behind SPY at 213.6%.

Ensysce Biosciences is a clinical-stage pharmaceutical company developing prescription drugs designed to address severe pain relief while mitigating risks of opioid misuse, abuse, and overdose. The company's pipeline includes products using proprietary platforms—Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR)—with lead candidates targeting chronic pain, ADHD, and opioid use disorder, along with neuroplastogenic therapies for complex regional pain syndrome. As an early-stage biotech company, it does not currently distribute to shareholders and operates with no established expense ratio or asset base metrics typical of operating businesses.

ENSC performance versus SPY

Price and return data through 2026-10-16.

Total return is -100.0% over the past 8.6 years, 313.6 points behind SPY at 213.6%. Over the past year its total return — price change plus distributions reinvested — is -79.8%. Its deepest 1-year drawdown was 90.2%.

ENSC key facts

Asset type

Stock

Asset class

Equity

Inception date

02/26/2018

Distribution frequency

None

Last close

$0.52 (as of 2026-10-16)

Market cap

$10,084,456

Average volume

490285.0

Beta

1.016

Payout ratio

0.0%

Forward P/E

0.9496

EPS

$-2.47

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ENSC risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 90.2%.

Who may consider ENSC — and who may not

It is a weaker fit for investors who need monthly cash flow (ENSC does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ENSC

• All tickers starting with E

Tagged: Healthcare.

Frequently asked questions